Posts With Tag NSCLC

AstraZeneca's Imfinzi receives EMA approval recommendation for NSCLC. AEGEAN trial shows significant recurrence reduction, enhancing patient outcomes and market potential.

HUTCHMED (China) Limited's SEC Form 6-K reveals full NMPA approval for ORPATHYS, enhancing market prospects for treating advanced NSCLC. Filed January 14, 2025.